TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis.

There is considerable evidence that osteoclasts are involved in the pathogenesis of focal bone erosion in rheumatoid arthritis. Tumor necrosis factor-related activation-induced cytokine, also known as receptor activator of nuclear factor-kappaB ligand (TRANCE/RANKL) is an essential factor for osteoclast differentiation. In addition to its role in osteoclast differentiation and activation, TRANCE/RANKL also functions to augment T-cell dendritic cell cooperative interactions. To further evaluate the role of osteoclasts in focal bone erosion in arthritis, we generated inflammatory arthritis in the TRANCE/RANKL knockout mouse using a serum transfer model that bypasses the requirement for T-cell activation. These animals exhibit an osteopetrotic phenotype characterized by the absence of osteoclasts. Inflammation, measured by clinical signs of arthritis and histopathological scoring, was comparable in wild-type and TRANCE/RANKL knockout mice. Microcomputed tomography and histopathological analysis demonstrated that the degree of bone erosion in TRANCE/RANKL knockout mice was dramatically reduced compared to that seen in control littermate mice. In contrast, cartilage erosion was present in both control littermate and TRANCE/RANKL knockout mice. These results confirm the central role of osteoclasts in the pathogenesis of bone erosion in arthritis and demonstrate distinct mechanisms of cartilage destruction and bone erosion in this animal model of arthritis.

[1]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[2]  N. Udagawa,et al.  A novel molecular mechanism modulating osteoclast differentiation and function. , 1999, Bone.

[3]  S. Goldring,et al.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. , 2000, Arthritis and rheumatism.

[4]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[5]  G. Roodman,et al.  Sequential expression of phenotype markers for osteoclasts during differentiation of precursors for multinucleated cells formed in long-term human marrow cultures. , 1990, Endocrinology.

[6]  S. Goldring,et al.  Expression of the calcitonin receptor in bone marrow cell cultures and in bone: a specific marker of the differentiated osteoclast that is regulated by calcitonin. , 1995, Endocrinology.

[7]  G. Hattersley,et al.  Generation of osteoclastic function in mouse bone marrow cultures: multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. , 1989, Endocrinology.

[8]  J. Lian,et al.  A role for osteocalcin in osteoclast differentiation , 1991, Journal of cellular biochemistry.

[9]  V. Kouskoff,et al.  Organ-Specific Disease Provoked by Systemic Autoimmunity , 1996, Cell.

[10]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[12]  C. Benoist,et al.  Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. , 1999, Science.

[13]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[14]  Yongwon Choi,et al.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Ochi,et al.  Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis. , 2001, Rheumatology.

[16]  Kozo Nakamura,et al.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[17]  Y. Ito,et al.  Gene expression during osteoclast-like cell formation induced by antifusion regulatory protein-1/CD98/4F2 monoclonal antibodies (MAbs): c-src is selectively induced by anti-FRP-1 MAb. , 1999, Bone.

[18]  R. Steinman,et al.  Trance, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells in Vivo , 2000, The Journal of experimental medicine.

[19]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[20]  D. Woolley,et al.  Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. , 1984, Arthritis and rheumatism.

[21]  D. Gauguier,et al.  Genetic Influences on the End-Stage Effector Phase of Arthritis , 2001, The Journal of experimental medicine.

[22]  R. Boyce,et al.  NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. , 1989, International journal of tissue reactions.

[23]  J. Frazier,et al.  Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. , 1999, Arthritis and rheumatism.

[24]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[25]  Y. Suzuki,et al.  Osteoclast-like cells in murine collagen induced arthritis. , 1998, The Journal of rheumatology.

[26]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[27]  P Rüegsegger,et al.  Micro-tomographic imaging for the nondestructive evaluation of trabecular bone architecture. , 1997, Studies in health technology and informatics.

[28]  T. Martin,et al.  Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. , 2000, Arthritis and rheumatism.

[29]  D. Lacey,et al.  Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors , 1999, Journal of cellular biochemistry.

[30]  P. Rüegsegger,et al.  Morphometric analysis of human bone biopsies: a quantitative structural comparison of histological sections and micro-computed tomography. , 1998, Bone.

[31]  T. Thornhill,et al.  Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. , 1998, The American journal of pathology.

[32]  L. Holliday,et al.  Initiation of Osteoclast Bone Resorption by Interstitial Collagenase* , 1997, The Journal of Biological Chemistry.

[33]  K. Rajewsky,et al.  From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. , 1999, Immunity.

[34]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[35]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  Steffen Jung,et al.  Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance , 2000, The Journal of experimental medicine.

[37]  Thomas Pap,et al.  Arthritis , 2000, Nature Biotechnology.

[38]  B. Dijkmans,et al.  Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. , 1996, Arthritis and rheumatism.

[39]  P. Geusens,et al.  Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.

[40]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[41]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[42]  P. Petrow,et al.  Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. , 1998, The Journal of rheumatology.

[43]  K. Balto,et al.  Quantification of Periapical Bone Destruction in Mice by Micro-computed Tomography , 2000, Journal of dental research.

[44]  G. Hattersley,et al.  Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. , 1989, Endocrinology.

[45]  T. Hotokebuchi,et al.  Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. , 1998, Histology and histopathology.

[46]  P Rüegsegger,et al.  Non-invasive bone biopsy: a new method to analyse and display the three-dimensional structure of trabecular bone. , 1994, Physics in medicine and biology.

[47]  J. Riddle,et al.  The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. , 1988, The Journal of rheumatology.

[48]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.